UNCY

Unicycive Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↑ 7/10
  • Momentum↑ 6/10
Unicycive Therapeutics sales and earnings growth
UNCY Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 53.12%
  • FCF Y/Y↓ -12.68%
Unicycive Therapeutics gross and profit margin trends
UNCY Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↑ 368.10%
Unicycive Therapeutics net debt vs free cash flow
UNCY Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -530.3

Unicycive Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗